ESSA Pharma (EPIX) Sets New 1-Year Low at $0.20
Shares of ESSA Pharma Inc. (NASDAQ:EPIX) (TSE:EPI) reached a new 52-week low during trading on Tuesday . The company traded as low as $0.20 and last traded at $0.22, with a volume of 24700 shares. The stock had previously closed at $0.21.
A number of analysts have recently commented on EPIX shares. Zacks Investment Research upgraded ESSA Pharma from a “hold” rating to a “buy” rating and set a $0.50 price objective for the company in a report on Monday, September 11th. Bloom Burton downgraded ESSA Pharma from a “buy” rating to a “hold” rating in a report on Tuesday, September 12th. One analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $4.75.
The company has a current ratio of 1.26, a quick ratio of 1.26 and a debt-to-equity ratio of -1.32.
About ESSA Pharma
ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses on the development of novel and proprietary therapies for the treatment of prostate cancer. Its product candidate is EPI-506, an oral small molecule pro-drug that is in Phase 1/2 clinical trial, which blocks the N-terminal domain of the androgen receptor.
Receive News & Ratings for ESSA Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma and related companies with MarketBeat.com's FREE daily email newsletter.